Chief Medical Officer Moss Ronald B. sale 8,199 shares of Adamis Pharmaceuticals Corporation [ADMP]

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Adamis Pharmaceuticals Corporation shares valued at $4,949 were sold by Moss Ronald B. on Mar 18. At $0.60 per share, Moss Ronald B. sold 8,199 shares. The insider’s holdings dropped to 201,911 shares worth approximately $52496.86 following the completion of this transaction.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored


Also, Marguglio David J. sold 11,859 shares, netting a total of over 7,117 in proceeds. Following the sale of shares at $0.60 each, the insider now holds 233,906 shares.

Before that, CARLO DENNIS J PHD had sold 10,490 shares from its account. In a trade valued at $6,287, the President & CEO traded Adamis Pharmaceuticals Corporation shares for $0.60 each. Upon closing the transaction, the insider’s holdings decreased to 10,490 shares, worth approximately $74325.42.

As published in a research note from Maxim Group on May 13, 2020, Adamis Pharmaceuticals Corporation [ADMP] has been rated up from a Hold to a Buy and the price target has been revised to $1.50. This represents a 82.67% premium over Wednesday’s closing price. Analysts at Dawson James downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in late February. As of November 26, 2019, Raymond James has decreased its “an Outperform” rating to a “Mkt perform” for ADMP. Earlier on July 16, 2019, B. Riley FBR downgraded its rating. Their new recommendation was “a Sell” for ADMP stock which previously was a “a Neutral”.

Analyzing ADMP’s Price Performance

On Wednesday, Adamis Pharmaceuticals Corporation [NASDAQ: ADMP] plunged -28.26% to $0.26. The stock’s lowest price that day was $0.181, but it reached a high of $0.27 in the same session. During the last five days, there has been a drop of approximately -22.55%. Over the course of the year, Adamis Pharmaceuticals Corporation shares have dropped approximately -57.37%. Shares of the company reached a 52-week high of $0.8477 on 01/10/22 and a 52-week low of $0.1810 on 09/21/22. A 50-day SMA is recorded $0.3656, while a 200-day SMA reached $0.4992. Nevertheless, trading volume fell to 5.96 million shares from 0.44 million shares the previous day.

Support And Resistance Levels for Adamis Pharmaceuticals Corporation (ADMP)

According to the 24-hour chart, there is a support level at 0.2026, which, if violated, would cause prices to drop to 0.1473. In the upper region, resistance lies at 0.2916. The next price resistance is at 0.3253. RSI (Relative Strength Index) is 30.14 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0062, which suggests the price will decrease in the coming days. Percent R is at 60.16%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Adamis Pharmaceuticals Corporation subject to short interest?

Stocks of Adamis Pharmaceuticals Corporation saw a sharp steep in short interest on Jul 14, 2022 dropping by -0.64 million shares to 5.62 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 6.26 million shares. A decline of -11.39% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 12.68 of the overall float, the days-to-cover ratio (short ratio) decline to 12.68.

Which companies own the most shares of Adamis Pharmaceuticals Corporation (ADMP)?

According to The Vanguard Group, Inc. filings, the company currently owns 6,423,273 shares, which is about 4.28% of the total ADMP shares outstanding. With the completion of the buy transaction, BlackRock Fund Advisors’s stake is now worth $928,089. Geode Capital Management LLC acquire a 5.57% interest valued at $0.45 million while SSgA Funds Management, Inc. 0 stake. In its current portfolio, Private VermögensVerwaltung AG holds 115,000 shares valued at $38295.0.

In terms of Adamis Pharmaceuticals Corporation share price expectations, FactSet research, analysts set an average price target of $1.50 in the next 12 months, up nearly 316.67% from the previous closing price of $0.36. Analysts anticipate Adamis Pharmaceuticals Corporation stock to reach $1.50 by 2022, with the lowest price target being $1.50. On November 12, 2018, B. Riley FBR assigned a price target of “a Neutral” to the stock and downgraded coverage with a $2.50.

LEAVE A REPLY

Please enter your comment!
Please enter your name here